FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:539-540 August 15, 2002 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The tyrosine kinase inhibitor imatinib mesylate specifically inhibits the BCR-ABL kinase, and has shown promising results in phase 1 and 2 trials in patients with chronic myelogenous leukemia at various stages of the disease.^1,2 We describe a patient in whom a complete molecular response was achieved with no evidence of BCR-ABL messenger RNA (mRNA) six months after treatment with imatinib began.

A 58-year-old man with Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia in chronic phase was initially treated with interferon alfa followed by intensive chemotherapy plus granulocyte colony-stimulating factor, which allowed the successful collection of Ph-negative blood stem . . . [Full Text of this Article]

This article has been cited by other articles:

• Lange, T., Niederwieser, D. W., Deininger, M. W.N. (2003). Residual Disease in Chronic Myeloid Leukemia after Induction of Molecular Remission. NEJM 349: 1483-1484 [Full Text]  
• Lin, F., Drummond, M., O'Brien, S., Cervantes, F., Goldman, J., Kaeda, J. (2003). Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood 102: 1143-1143 [Full Text]